Fabrication of isradipine nanosuspension by anti-solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability

Drug Delivery and Translational Research

Volumn 3, Issue 5, 2013, Pages 384-391

  Shelar, Dnyanesh B ^a   Pawar, Smita K ^a   Vavia, Pradeep R ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

High pressure homogenization; Isradipine; Nanosuspension; Pharmacokinetic

Indexed keywords

APREPITANT; DODECYL SULFATE SODIUM; FENOFIBRATE; ISRADIPINE; MEGESTROL ACETATE; NPI 32101; RAPAMMUNE; STABILIZING AGENT; TOCOFERSOLAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTISOLVENT MICROPRECIPITATION; AREA UNDER THE CURVE; ARTICLE; CHEMICAL PROCEDURES; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HIGH PRESSURE HOMOGENIZATION; LASER DIFFRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSUSPENSION; NANOSUSPENSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PRECIPITATION; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84883442768     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0081-3     Document Type: Article

References (23)

1. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. preparation by a size reduced technique. Int J Pharm. 1998;160: 229-37.
2. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409: 260-8.
3. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47: 3-19.
4. Liversidge EM, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63: 427-40.
5. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3: 785-96.
6. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm. 2002;237(1-2): 151-61.
7. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharma Pharmacol. 2004;56: 827-40.
8. Singh SK, Srinivasan KK, Gowthamarajan K, Singare DS, Prakash D, Gaikwad NB. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm. 2011;78: 441-6.
9. VanEerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, et al. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm. 2007;338: 198-206.
10. Pua X, Suna J, Wanga Y, Wang Y, Liua X, Zhanga P, et al. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm. 2009;379: 167-73.
11. Fitton A, Benfield P. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs. 1990;40(1): 31-74.
12. Walton T, Symes LR. Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. Clin Pharm. 1993;12(4): 261-75.
13. Libo W, Jian Z, Wiwik W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63: 456-69.
14. Varma MVS, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25: 445-53.
15. United States Pharmacopeial Convention. United States Pharmacopeia and National Formulary (USP 30-NF 25). Rockville, MD: United States Pharmacopeial Convention. 2007; 2: 531-533.
16. United States Pharmacopeial Convention. United States Pharmacopeia and National Formulary (USP 30-NF 25). Rockville, MD: United States Pharmacopeial Convention. 2007; 2: 2432-2435.
17. Tse FLS, Jaffe JM, Hassell AE, Schran HF. Bioavailability of isradipine in young and old rats: effect of mode of administration. J Pharm Pharmacol. 1989;41: 657-60.
18. Lindfors L, Forssn S, Skantze P, Skantze U, Zackrisson A, Olsson U. Amorphous drug nanosuspensions 2. Experimental determination of bulk monomer concentrations. Langmuir. 2006;22: 911-6.
19. Muller RH, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19: 189-94.
20. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir. 2006;22: 906-10.
21. Oppenheim RC, Marty JJ, Speiser PP. Injectable compositions, nanoparticles useful therein, and process of manufacturing same US 4107288. 1978.
22. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 1989;51: 9-17.
23. Jia L, Wong H, Cerna C, Weitman SD. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res. 2002;19: 1091-6.